Mesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platforms

doi:10.4252/wjsc.120363

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 7

This Article

(19)

(20)

(0)

(13)

(587)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Stem Cells. Jul 26, 2026; 18(7): 120363
Published online Jul 26, 2026. doi: 10.4252/wjsc.120363

Table 4 Translational bottlenecks and mitigation approaches

Translational challenge	Impact on clinical translation	Proposed mitigation strategy	Ref.
Batch heterogeneity	Variable efficacy	Standardized MSC banking	[180]
Donor variability	Product heterogeneity	Defined donor selection criteria	[21]
Low scalability	Limited clinical production	Bioreactor + TFF systems-based manufacture	[181]
Stability issues	Cold-chain dependence	Lyophilization with trehalose	[182]
Regulatory ambiguity	Delayed approval	Early regulator	[183]
Potency assay standardization	Difficulty assessing therapeutic activities	Functional bioassay validation	[180]
Comparability after process change	Regulatory approval risk	Analytical comparability testing	[177]
Storage stability limitations	Reduced shelf-life	Cryopreservation optimization	[182]
Cost effectiveness	Manufacturing feasibility concerns	Process automation	[181]

MSC: Mesenchymal stem cell; TFF: Tangential flow filtration.

Full Size Table

Citation: Khan SA, Jha SK, Tiwari P, Narang J, Gupta V, Singh SK, Anand K, Rajendran RL, Gangadaran P, Parvez S. Mesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platforms. World J Stem Cells 2026; 18(7): 120363
URL: https://www.wjgnet.com/1948-0210/full/v18/i7/120363.htm
DOI: https://dx.doi.org/10.4252/wjsc.120363

Khan SA, Jha SK, Tiwari P, Narang J, Gupta V, Singh SK, Anand K, Rajendran RL, Gangadaran P, Parvez S. Mesenchymal stem cell-derived extracellular vesicles as next generation drug delivery platforms. World J Stem Cells 2026; 18(7): 120363 [DOI: 10.4252/wjsc.120363]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.